Rocket Pharmaceuticals, Inc.RCKTNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-8.10%
↓ 113% below average
Average (9y)
64.48%
Historical baseline
Range
High:275.33%
Low:-55.63%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| 2024 | -8.10% |
| 2023 | 12.55% |
| 2022 | 31.95% |
| 2021 | 17.95% |
| 2020 | 81.47% |
| 2019 | 10.05% |
| 2018 | 275.33% |
| 2017 | -55.63% |
| 2016 | 154.78% |
| 2015 | 124.50% |